Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer

被引：0

作者：

Chen, David C. ^{[1
]}

AlSaffar, Haidar ^{[1
]}

Graefen, Henrike ^{[1
,2
]}

Perera, Sachin ^{[1
]}

Mazzone, Elio ^{[1
]}

Perera, Marlon L. ^{[1
,3
]}

Lawrentschuk, Nathan ^{[1
,4
,5
]}

Murphy, Declan G. ^{[1
,5
,6
]}

机构：

[1] Peter Maallum Canc Ctr, Div Canc Surg, Melbourne, Australia

[2] Univ Appl Sci & Med Univ, Med Sch Hamburg, Hamburg, Germany

[3] Univ Melbourne, Dept Urol, Austin Hlth, Heidelberg, Vic, Australia

[4] Royal Melbourne Hosp, Dept Urol, Melbourne, Australia

[5] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Australia

[6] Peter MacCallum Canc Ctr, Div Canc Surg, 305 Grattan St, Melbourne, Vic 3000, Australia

来源：

EUROPEAN UROLOGY | 2024年 / 86卷 / 03期

关键词：

D O I：

10.1016/j.eururo.2024.03.032

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

chemotherapy alone in cisplatin-eligible patients with untreated la/mUC, were presented at the 2023 European lumab-based combinations and EV/P in cisplatin-eligible patients will be useful in determining potential differences in patient outcomes in distinct subpopulations. The EV-302/KEYNOTE-A39 study represents a transformative milestone in the first-line management of la/mUC. Nevertheless, it is always crucial to consider the toxicity profile and patient comorbidities when selecting candidates for the EV/P combination.

引用

页码：282 / 283

页数：2

共 5 条

[1] Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial [J].

Grivas, Petros ;

Park, Se Hoon ;

Voog, Eric ;

Caserta, Claudia ;

Gurney, Howard ;

Bellmunt, Joaquim ;

Kalofonos, Haralabos ;

Ullen, Anders ;

Loriot, Yohann ;

Sridhar, Srikala S. ;

Yamamoto, Yoshiaki ;

Petrylak, Daniel P. ;

Sternberg, Cora N. ;

Gupta, Shilpa ;

Huang, Bo ;

Costa, Nuno ;

Laliberte, Robert J. ;

di Pietro, Alessandra ;

Valderrama, Begona P. ;

Powles, Thomas .

EUROPEAN UROLOGY, 2023, 84 (01) :95-108

[2] Checkpoint Inhibitors in Urothelial Carcinoma-Future Directions and Biomarker Selection [J].

Meeks, Joshua J. ;

Black, Peter C. ;

Galsky, Matthew ;

Grivas, Petros ;

Hahn, Noah M. ;

Hussain, Syed A. ;

Milowsky, Matthew I. ;

Steinberg, Gary D. ;

Svatek, Robert S. ;

Rosenberg, Jonathan E. .

EUROPEAN UROLOGY, 2023, 84 (05) :473-483

[3] Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer [J].

Powles, T. ;

Valderrama, B. P. ;

Gupta, S. ;

Bedke, J. ;

Kikuchi, E. ;

Hoffman-Censits, J. ;

Iyer, G. ;

Vulsteke, C. ;

Park, S. H. ;

Shin, S. J. ;

Castellano, D. ;

Fornarini, G. ;

Li, J. R. ;

Guemues, M. ;

Mar, N. ;

Loriot, Y. ;

Flechon, A. ;

Duran, I ;

Drakaki, A. ;

Narayanan, S. ;

Yu, X. ;

Gorla, S. ;

Moreno, B. Homet ;

van der Heijden, M. S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (10) :875-888

[4] Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up [J].

Powles, Thomas ;

Park, Se Hoon ;

Caserta, Claudia ;

Valderrama, Begona P. ;

Gurney, Howard ;

Ullen, Anders ;

Loriot, Yohann ;

Sridhar, Srikala S. S. ;

Sternberg, Cora N. N. ;

Bellmunt, Joaquim ;

Aragon-Ching, Jeanny B. B. ;

Wang, Jing ;

Huang, Bo ;

Laliberte, Robert J. J. ;

di Pietro, Alessandra ;

Grivas, Petros .

JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (19) :3486-+

[5] Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma [J].

Powles, Thomas ;

Rosenberg, Jonathan E. ;

Sonpavde, Guru P. ;

Loriot, Yohann ;

Duran, Ignacio ;

Lee, Jae-Lyun ;

Matsubara, Nobuaki ;

Vulsteke, Christof ;

Castellano, Daniel ;

Wu, Chunzhang ;

Campbell, Mary ;

Matsangou, Maria ;

Petrylak, Daniel P. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (12) :1125-1135

← 1 →